Klaria Pharma

The year in brief

- Net sales amounted to 9.0 MSEK (2.2 MSEK)

- Other operating income amounted to 0.0 MSEK (0.1 MSEK)

- R&D costs amounted to 28.3 MSEK (22.1 MSEK)

- Profit/loss after tax amounted to -47.1 MSEK (-47.8 MSEK)

- Earnings per share amounted to -0.25 SEK (-0.38 SEK)

- Cash flow from operations amounted to -34.2 MSEK (-11.9 MSEK)

- Shareholder’s equity as of December 31, 2025 amounted to -12.0 MSEK (3.3 MSEK)

- Cash and cash equivalents as of December 31, 2025 amounted to 0.3 MSEK (0.6 MSEK)